✅ No sanctions, screening, insolvency or control red flags found in the public sources we cover. (Absence of a flag is not a guarantee — see methodology.)
BIOPATH UNILABS
SAS · Active since 1996
Overview
BIOPATH UNILABS is a simplified joint-stock company registered in bry-sur-marne, France, since 1996. With reported revenue of 57.2M EUR in 2024. Its TraceComp score of 90 (A+) indicates solid fundamentals and low apparent risk. With 30 years of operations, the company has an established track record in its market.
Company Information
- Registration Number
- 403916596
- Legal Form
- SAS
- Registered
- 1996-05-06
- Address
- bry-sur-marne
Financial Profile
Latest filed accounts: FY 2024
Multi-year financials & ratios
5 years of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Officers & Management
3 officers/directors on file — names, roles, appointment & resignation dates.
| Name | Role | Status |
|---|---|---|
| JEROME JACQUES AUGUSTIN MOTOL | Président de SAS | Current |
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Public Contracts Won
Awarded 1 public-sector contract totalling EUR 6 (DECP).
Which public buyers, contract titles, values and award dates.
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Risk Signals
No adverse legal events have been recorded for this company.
- Profitable: positive net income in FY 2024
- Altman Z-Score in the safe zone
Data Sources & Freshness
Data sourced from: official public registries.